why choose us

First received: October 25, 2023

Clinical Trial: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Study Status: Completed

Recruit Status: RECRUITING

Condition: Non Muscle Invasive Bladder Cancer

Study Type: INTERVENTIONAL


Official Title: A Phase 3, Randomized Study of Adjuvant Cretostimogene Grenadenorepvec Versus Observation for the Treatment of Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR-NMIBC) Following Transurethral R

Brief Summary: This is a Phase 3, open-label, randomized trial designed to evaluate the RFS of TURBT followed by cretostimogene grenadenorepvec versus TURBT followed by observation for the treatment of participants with IR-NMIBC.

Read more